Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
pharmaphorum5d
Lilly says Mounjaro launch is "viral in nature"
The launch of Mounjaro always raised the risk that it would cannibalise sales of Lilly's own GLP-1 agonist Trulicity (dulaglutide), which is competing head-to-head with Ozempic in the market ...
Hosted on MSN9mon
IBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
This pushed Lilly to raise its sales outlook for the year by $2 billion, despite short revenue from diabetes treatments Mounjaro and Trulicity. Analysts noted Eli Lilly and its biggest rival ...
pharmaphorum2y
Lilly injects $450m into plant making Mounjaro
which will help it meet what it anticipates will be rising demand for Mounjaro and other drugs in its incretin franchise, notably blockbuster GLP-1 agonist Trulicity (dulaglutide). "Expanding our ...